Next Article in Journal
The Impact of Human Lipoaspirate and Adipose Tissue-Derived Stem Cells Contact Culture on Breast Cancer Cells: Implications in Breast Reconstruction
Next Article in Special Issue
Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112)
Previous Article in Journal
Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation
Previous Article in Special Issue
The Potential Role of Hepatocyte Growth Factor in Degenerative Disorders of the Synovial Joint and Spine

Targeting HGF/c-MET Axis in Pancreatic Cancer

Pancreatic Research Group, South Western Sydney Clinical School, Faculty of Medicine and Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia
Faculty of Medicine, The University of New South Wales, Sydney, NSW 2052, Australia
Author to whom correspondence should be addressed.
These authors contribute equally to this work.
Int. J. Mol. Sci. 2020, 21(23), 9170;
Received: 30 October 2020 / Revised: 27 November 2020 / Accepted: 28 November 2020 / Published: 1 December 2020
(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF), II)
Pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC/PC)) has been an aggressive disease that is associated with early metastases. It is characterized by dense and collagenous desmoplasia/stroma, predominantly produced by pancreatic stellate cells (PSCs). PSCs interact with cancer cells as well as other stromal cells, facilitating disease progression. A candidate growth factor pathway that may mediate this interaction is the hepatocyte growth factor (HGF)/c-MET pathway. HGF is produced by PSCs and its receptor c-MET is expressed on pancreatic cancer cells and endothelial cells. The current review discusses the role of the MET/HGF axis in tumour progression and dissemination of pancreatic cancer. Therapeutic approaches that were developed targeting either the ligand (HGF) or the receptor (c-MET) have not been shown to translate well into clinical settings. We discuss a two-pronged approach of targeting both the components of this pathway to interrupt the stromal–tumour interactions, which may represent a potential therapeutic strategy to improve outcomes in PC. View Full-Text
Keywords: HGF-c-MET; Pancreatic Cancer; Stromal-tumour interactions HGF-c-MET; Pancreatic Cancer; Stromal-tumour interactions
Show Figures

Figure 1

MDPI and ACS Style

Pothula, S.P.; Xu, Z.; Goldstein, D.; Pirola, R.C.; Wilson, J.S.; Apte, M.V. Targeting HGF/c-MET Axis in Pancreatic Cancer. Int. J. Mol. Sci. 2020, 21, 9170.

AMA Style

Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET Axis in Pancreatic Cancer. International Journal of Molecular Sciences. 2020; 21(23):9170.

Chicago/Turabian Style

Pothula, Srinivasa P., Zhihong Xu, David Goldstein, Romano C. Pirola, Jeremy S. Wilson, and Minoti V. Apte. 2020. "Targeting HGF/c-MET Axis in Pancreatic Cancer" International Journal of Molecular Sciences 21, no. 23: 9170.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop